Home

ARNOLD C HANISH

CIK 1233253 · Chief Accounting Officer · last filed 2026-09-02

ARNOLD C HANISH is a Chief Accounting Officer who has filed 55 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing, for DCOY, was dated Sep 2, 2026. Across all open-market trades the lifetime net is −$613.5K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $29.8M across reported positions. 12 SEC filings were submitted jointly with LILLY & Co ELI.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$29.82M

Companies

4

Total Filings

55

Lifetime Open-Market Net

-$613.5K

Filer Profile

Reported Address
201 ELLIOTT AVENUE WEST
SEATTLE, WA 98119
Related Filers
LILLY & Co ELI — 12 joint filings, latest 2012-10-30
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
DCOY Director 3,418 $2.79 $9.5K $0 1 2026-09-02
OMER Director 17,400 $19.01 $330.8K -$303.2K 19 2026-08-28
Salarius Pharmaceuticals, Inc. (SLRX) Delisted Director 5,000 $0.84 $4.2K $65.2K 18 2026-01-02
LLY Chief Accounting Officer 26,201 $1125.15 $29.48M -$375.5K 14 2012-10-30

Recent Filings

55 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-09-02 DCOY Grant (A) +3,000 $0 EDGAR
2026-08-28 OMER Mixed — -$53.6K EDGAR
2026-08-27 OMER Notice (144) −10,000 -$189.5K EDGAR
2026-08-26 OMER Notice (144) −5,000 -$94.1K EDGAR
2026-06-22 OMER Grant (A) — $0 EDGAR
2026-01-02 Salarius Pharmaceuticals, Inc. (SLRX) Delisted Sell (S) −27 -$17 EDGAR
2025-11-24 Salarius Pharmaceuticals, Inc. (SLRX) Delisted Buy (P) +5,000 $3.7K EDGAR
2025-07-01 OMER Grant (A) — $0 EDGAR
2024-06-07 OMER Grant (A) — $0 EDGAR
2024-02-22 Salarius Pharmaceuticals, Inc. (SLRX) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 55
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.